We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 1.77% | 11.50 | 11.00 | 12.00 | 12.25 | 11.25 | 11.50 | 704,699 | 09:48:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 2.19M | -1.44M | -0.0232 | -4.96 | 7.01M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/4/2024 14:44 | Can anyone smell BS. | albert35911 | |
10/4/2024 14:32 | 94000 shares buy just gone through. Big buys arriving | letsbuy1 | |
10/4/2024 08:13 | Big push up any sec. They are searching for stock. No float at all | letsbuy1 | |
10/4/2024 07:58 | Dropping it to gather shares. Dont give it to them.. this will be 13/14p later today | letsbuy1 | |
09/4/2024 08:26 | Timely update. No horrors for once. So much potential but can they finally deliver. My guess is Ian Ardill will be playing a key role in the graft project given his background and experience. We will see chop with every move up as the placing supporters take their slim gains. Ultimately, Mr Brown needs to turn this around from the dog it has become, something he mentioned that he would target doing following the name change from AOR. | early not wrong | |
08/4/2024 12:48 | Hopefully see some healthy consolidation around this level before the next leg up. | parob | |
08/4/2024 08:41 | Cavendish retain their 25p price target in their update this morning (with a £7.8m m/cap at 12.5p). Brief extracts: "Strong strategic progress RUA Life Sciences has provided a business update for the year to March 2024, noting revenue shortfalls experienced in H1/24 have been made up by a strong second half. Revenues for the year are therefore expected to be in-line with our forecast £2.2m, while the company notes gross margin will exceed our forecasts, with operating costs remaining tightly controlled. RUA Life Sciences closed FY24 with cash of c£4.0m versus our £3.3m estimate. The company reports significant progress towards its goal of near-term profitability through growing its contract manufacturing business, noting strong progress with a ‘global enterprise’. Finally, RUA has completed a Material Transfer Agreement with a global Heart Valve company covering its composite heart valve material. We believe this update demonstrates excellent progress against the company’s revised strategy." "Strategy – As noted with its successful fundraise in December 2023, RUA’s revised strategy will seek to grow its Contract Manufacturing business, generating long-term contract revenues, explore third-party funding for its vascular graft portfolio and pursue licence opportunities for its composite heart valve material. We believe this business update demonstrates strong progress against this strategy. - Investment thesis – We believe the combination of established revenues with growth potential and the option to deliver significant returns through the disruption of established billion-dollar global cardiovascular markets makes RUA Life Sciences an attractive investment opportunity. RUA now aims to turn profitable in the short term and has adopted a strategy to deliver earlier returns on its Vascular and Structural Heart investments." | rivaldo | |
07/4/2024 14:00 | I think operating costs excludes COS without much doubt. But let's see numbers when they come out | harrogate | |
07/4/2024 13:00 | You may have a point there Harrogate. I was assuming the reference to operating costs was all costs since he paired it with a gross revenue number. These updates always seem to contain a certain amount of ambiguity! | bones | |
06/4/2024 13:25 | Think you need to take off around £400k for cost of sales from that revenue number | harrogate | |
06/4/2024 12:58 | Based on the update, the operating costs for full year to 31/3/24 were approx £3.4M. Assuming that is essentially all of the company’s costs, the operating loss should be around £1.2M using the £2.2M turnover highlighted. It’s not clear if another tax credit is in the offing for these numbers but probably not until later this year. If it is a £1.2M loss for the year, that is an encouraging change since the interim loss was on its own £1M (after tax credit receipt), meaning the H2 loss was only £200k. We don’t have a lot more to go on though! Likewise, the loss for the year before (ending 31/3/23) was £2.0M (after tax credit) and this year looks to be £1.2M. Again, a much improved (or less painful) scenario. Let’s hope the anticipated new business prospects in contract manufacturing continue to build while costs continue to be reduced. All the while, we hope for partnership developments in heart valve and vascular to manifest themselves! | bones | |
06/4/2024 08:54 | Nice one LITTLE man. When anyone gets personal it's a sign that they have lost the debate. Get a life you're such a pathetic LOSER. Lets remind peeps again this is all to do with you losing £2500 in PPP and you being a THICKO believe it's my fault. LOL hahahahahahahahah | z1co | |
05/4/2024 22:30 | Insane volume today. Combined with relative up move in price seems to bode well for further improvement over the coming weeks: free stock charts from uk.advfn.com | bones | |
05/4/2024 16:37 | Well, possibly, parsons4! He’s keeping his powder dry on the vascular graft side. Will it be possible to find a partner or financier to cover the clinical trials that are sat waiting to go with FDA protocols agreed? At least for now, no more costs of note are needed for that development while it is mothballed. Let’s hope, like they say they are actively pursuing, that they sign up more “partners̶ | bones | |
05/4/2024 15:56 | Well BB seems to have delivered in terms of catching up for the year and the " heart valve story" is looking good. After the disastrous placing and RNS shenanigans late last year the ship does seem steadier !!! A good close above the placing price also GLA | parsons4 | |
05/4/2024 15:46 | purple the clown, You made no difference at all , thicko try harder next time. Nice profitable trade. This game is far too easy for me. N I C E | z1co | |
05/4/2024 15:11 | CLOWN you're very funny hahahahahahahah | z1co | |
05/4/2024 15:10 | THATS THE END OF YOUR LITTLE RAMPING GAME HAHAHAHAH! | purple11 | |
05/4/2024 15:09 | YOURE NOT GOING TO BE ABLE TO POST ANYWHERE WITHOUT ME FOLLOWING ALONGSIDE EXPOSING YOU. HAHAHAHAH! | purple11 | |
05/4/2024 15:04 | you meanwhile are losing money all over the shop YOU ARE A CLOWN ZICO THE CLOWN | purple11 | |
05/4/2024 15:04 | i lost £400 in PPP in total. just another trade. | purple11 | |
05/4/2024 15:02 | You're a loser that's why you wanted a truce. hahahahahahahahahaha THICKO you also lost £2500 in PPP. hahahahahahahahahaha | z1co |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions